Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)

Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.

Tier C — InvestigationalInvestigationalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patient Summary

Is this FDA-cleared for this use?: Not FDA-cleared for chronic prostatitis / CPPS. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for CP/CPPS is investigational.
What evidence exists?: Tier C (investigational). Two small unblinded case series report NIH-CPSI score reductions; there are no randomized controlled trials. CP/CPPS (category III, chronic non-bacterial prostatitis) is multifactorial and best managed with a UPOINT-based multimodal approach: alpha-blockers, pelvic floor physiotherapy (often the highest-yield intervention), neuropathic pain agents, lifestyle changes, and addressing psychological / sexual / urinary symptom domains. Acute bacterial prostatitis is a distinct condition requiring antibiotics.
Main risks: Bleeding from bite sites for 6 to 24 hours after detachment in the perineum and lower abdomen
Bruising and tenderness in the perineum, sacrum, or suprapubic area for 5 to 10 days
Local skin infection or, rarely, Aeromonas infection
Allergic reaction to leech saliva (uncommon)
Temporary worsening of pelvic pain or urinary symptoms for 1 to 3 days
Small permanent scars at bite sites
Delay or replacement of pelvic floor physiotherapy and multimodal management
Who should not consider this: Patients with acute bacterial prostatitis (urinary infection, fever, severe pelvic pain — needs antibiotics)
Patients with prostate cancer on active surveillance or recent biopsy
Patients on anticoagulants, with hemophilia, or with severe anemia
Patients with active perianal or genital infection
Patients who have not been evaluated for UPOINT domains (urinary, psychosocial, organ-specific, infection, neurologic / systemic, tenderness)
Patients who have not tried pelvic floor physiotherapy with a qualified pelvic specialist
What to ask your clinician: Has acute bacterial prostatitis been excluded with urinalysis and culture?
Have I had a UPOINT phenotype evaluation, and what is my primary symptom domain?
Have I tried pelvic floor physiotherapy — the highest-evidence intervention?
Have I tried alpha-blockers (tamsulosin), and have neuropathic pain agents been considered?
Has central sensitization or psychological component been addressed (CBT, mindfulness)?
What is the practitioner's experience and Aeromonas-prevention plan? Will leeches be placed near genitalia or rectum?
What is the realistic chance of benefit and the cost?
When to seek urgent care: Fever, severe pelvic pain, inability to urinate, or visible blood in urine (acute bacterial prostatitis — urgent care)
Sudden severe testicular pain or swelling (torsion or epididymitis)
New constipation, bowel or bladder dysfunction, or saddle anesthesia (cauda equina — call 911)
Spreading redness, warmth, pus, or red streaks (cellulitis)
Bleeding from a bite site lasting more than 24 to 48 hours
Fever above 38.0 C / 100.4 F or chills
Hives, throat tightness, or breathing difficulty

What this does NOT mean

This is not FDA-cleared for chronic prostatitis or CPPS.
Unblinded case series with high placebo-response potential do NOT establish efficacy versus multimodal care.
Mechanism rationale (pelvic floor decongestion) does NOT replace pelvic floor physiotherapy.
Leech therapy is not a substitute for UPOINT-based multimodal management.
Acute bacterial prostatitis is a distinct condition that requires antibiotics, NOT complementary therapy.

Safety cross-references

Clinical Profile

Category: urogenital
ICD-10: N41.1, N41.9, N50.819
Safety tier: medium

Evidence Summary

No controlled clinical trial or published case series of leech therapy for category III chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) exists; any use is investigational and mechanistic only. Where attempted, leeches are placed at the perineum, sacrum, and lower abdomen — NEVER intra-rectally or peri-prostatically. A proposed mechanism involves pelvic-floor decongestion and modulation of central pain sensitization, but this is unproven. CP/CPPS is multifactorial and best managed with a UPOINT-based multimodal approach (alpha-blockers, pelvic-floor physical therapy, neuromodulators, lifestyle measures). Leech therapy could only be considered as an unproven exploratory adjunct.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

Soltani M et al. (2016), n=20

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Acute bacterial prostatitis
Prostate cancer under active surveillance

Related Conditions

Peyronie's Disease (Stable Phase)

Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.

Chronic Prostatitis / Chronic Pelvic Pain Syndrome (Extended Protocol)

Investigational extended-protocol adjunct for NIH Category III chronic prostatitis/CPPS; small case series only; UPOINT-directed therapy remains primary.

Interstitial Cystitis / Bladder Pain Syndrome (Investigational)

Highly investigational adjunct for IC/BPS refractory to conventional therapy; case reports only; AUA-guideline stepwise therapy remains primary.

Peyronie's Disease (Extended Investigational Adjunct)

Highly investigational extended-protocol adjunct for stable Peyronie's disease; case reports only; collagenase clostridium histolyticum and surgical correction remain primary.